Meeting
2023 ASCO Annual Meeting
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
Authors
Joseph J Zhao
Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore
Joseph J Zhao , Khi Yung Fong , Yiong Huak Chan , Jeremy Chee Seong Tey , Shaheenah S. Dawood , Soo-Chin Lee , Richard S. Finn , Raghav Sundar , Joline SJ Lim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1071)
DOI
10.1200/JCO.2023.41.16_suppl.1071
Abstract #
1071
Poster Bd #
292
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
First Author: Hope S. Rugo
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim